Lower MCT4 mRNA levels were observed in favorable-risk AMLs, compared to those observed in poor- and intermediate -risk group AMLs (Figure 4D), without any significant relationship between the recurrent gene mutations (Figure 4E) observed in AML and the level of MCT4 expression. The gene discussed is SLC16A3; the disease is acute myeloid leukemia.